chaitanyag11

According to the Batten Disease Support and Research Association, the batten disease has often been encountered in more than one children of the same family. The Daily News and Analysis article published in June 2016 suggests that, over 20 million children in India suffer from rare diseases, having expensive treatments. This creates opportunities for the sustaining as well as upcoming market players by understanding the potential held by the global batten disease treatment market.

Batten disease is a rare, inherent, and fatal autosomal recessive neural disorder that begins in the childhood but may take a few years to show symptoms.

Holter monitor is a battery-operated portable device that measures and records cardiac activity for 24 to 48 hours. Holter monitors device are used to detect and analyze cardiac arrhythmia, atrial fibrillation, and bradycardia. The device has silver dollar-sized electrodes, which can be attached to patients. The device is powered by small battery electrocardiogram (ECG) appliance. The system is incorporated with recorder and software to record heart rhythm and analyze the recorded data respectively. It is majorly used in patients diagnosed with coronary artery disease or post infarction period. According to the American Heart Association, around 17.3 million deaths are caused due to cardiovascular disease worldwide annually and number is anticipated to reach around 23.6 million by 2030. Increasing prevalence of cardiovascular disorders, adoption of preventive healthcare measures by population are key drivers for growth of global holter monitoring market.

Holter Monitor Market Taxonomy

On the basis of Product Type, Holter Monitor Market is segmented into:

• Single channel

• Double channel

• Multi-channel

On the basis of End user, Holter Monitor Market is segmented into:

• Hospitals

• Ambulatory surgical center

• Clinic

• Homecare

Request A Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/937

Increasing prevalence of cardiovascular diseases around the globe is expected to fuel growth of the holter monitor market over the forecast period

On the basis of Geography, Holter Monitor Market is segmented into North America, Latin America, Asia Pacific, Middle East and Europe. Increasing geriatric population and adoption of advanced healthcare facilities by patients are major factors expected to drive the growth of global cardiac holter monitor market over the forecast period. Geriatric population is more prone to heart diseases as heart muscles loose the resistance and capability to respond to different pressure rates, in turn making them more susceptible to cardiac disorders. According to the Center for Disease Control and Prevention (CDC), in 2012, around 117 million adults were suffering from one or more chronic conditions. North America holds dominant position in holter monitor market, owing high adoption of minimally aggressive diagnostic tools by patients and supportive government regulations and funding for treatment of cardiovascular disorder. According to the report published by American Heart Association in 2015, an estimated 450,000 deaths due to cardiac disorders in the U.S.

The holter monitor device market of Asia Pacific region is expected to grow at significant rate over the forecast period, owing to increasing prevalence of chronic disorder cases and unhealthy nutrition habits among rural population. Increasing awareness regarding treatment of cardiac arrhythmia and atrial fibrillation along with various programs conducted by world health organization (WHO) for prevention of cardiovascular disorders are major factors fueling growth of the holter monitor market in Asia Pacific.

Integration of advanced technologies in medical devices is expected to boost growth of the market. For instance, in 2015, Philips healthcare incorporated wireless and Bluetooth technology in cardiac hotler monitoring device. Shifting manufactures method towards customer centric development of products is expected to propel growth of the global holter monitor market over the forecast period. Key players operating holter equipment market include GE Healthcare, FUKUDA DENSHI, Koninklijke Philips N.V., Philips Healthcare, Nasiff Associates, Inc., LifeWatch AG, Schiller AG, Fukuda Denishi Co. Ltd. Spacelabs Healthcare, and Welch Allyn.

Click To Reading More On Holter Monitor Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

According to the American Heart Association, around 17.3 million deaths are caused due to cardiovascular disease worldwide annually and number is anticipated to reach around 23.6 million by 2030. Increasing prevalence of cardiovascular disorders, adoption of preventive healthcare measures by population are key drivers for growth of global holter monitoring market.

The holter monitor device market of Asia Pacific region is expected to grow at significant rate over the forecast period, owing to increasing prevalence of chronic disorder cases and unhealthy nutrition habits among rural population. Increasing awareness regarding treatment of cardiac arrhythmia and atrial fibrillation along with various programs conducted by world health organization (WHO) for prevention of cardiovascular disorders are major factors fueling growth of the holter monitor market in Asia Pacific.

According to the American Heart Association, around 17.3 million deaths are caused due to cardiovascular disease worldwide annually and number is anticipated to reach around 23.6 million by 2030. Increasing prevalence of cardiovascular disorders, adoption of preventive healthcare measures by population are key drivers for growth of global holter monitoring market.

Holter monitor is a battery-operated portable device that measures and records cardiac activity for 24 to 48 hours. Holter monitors device are used to detect and analyze cardiac arrhythmia, atrial fibrillation, and bradycardia. The device has silver dollar-sized electrodes, which can be attached to patients. The device is powered by small battery electrocardiogram (ECG) appliance. The system is incorporated with recorder and software to record heart rhythm and analyze the recorded data respectively.

Diabetic Neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. An estimated 50% of diabetic population suffers from diabetic neuropathy across the globe. Further, as per CDC estimates,   6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the U.S. Rise in aging population coupled with rise in prevalence of diabetes, the patient pool for diabetic neuropathy will increase significantly, in turn fueling growth of the diabetic neuropathy market.

New drugs to treat neuropathy pain will alter the current market dynamics

The diabetic neuropathy market has been under continuous evolution from the past 5 years. There are generic drugs and specialty drugs including antidepressants and antispasmodics, as well to treat pain associated with the disorder. However, in 2011, there were an estimated 79 novel drugs in the clinical trial phase with Horizant (Gabapentin Enacarbil extended release) being one of the most effective drug. The pharmaceutical companies will continue the required geographic expansion and release novel drugs across major countries in different regions. Further, the growing awareness about diabetic neuropathy, increased healthcare spending and increase in pharmaceutical R&D spending will be important factors for growth in the diabetic neuropathy market.

Asia Pacific region will be the next frontier of growth in the global diabetic neuropathy market

North America is the largest market for diabetic neuropathy, with an estimated 35 million affected by the disease in U.S and Canada. The pharmaceutical companies continue to introduce novel drugs in the region in order to offset the generic drug erosion. Diabetic neuropathy treatment has gained immense traction especially in U.S. due to large patient pool, high incidence of diabetes and growing geriatric population. However, the strict regulatory scenario for drug approval in U.S. and Canada has been a challenge for the diabetic neuropathy market. Other factors such as significant rate of failure during clinical trials and long drug approval time continue to restrain the growth in industry.

Get PDF Brochure of This Business Report:

https://www.coherentmarketinsights.com/insight/request-pdf/213

Asia Pacific region is fastest growing region with countries such as India and China showing lucrative growth. India has one of the highest rates of diabetes type 2 in the world and according to an independent research, by year 2030, an estimated 80 million people will be affected with diabetes type 2 in India. Additionally, the study concluded that the prevalence rate for diabetic neuropathy was 29% in the entire patient population. China has edged India and has a diabetes patient population of 110 million which is projected to reach 150 million by 2040, as per data published by WHO. Major pharmaceutical companies are now venturing into Asia pacific region and the market is poised to witness substantial growth in the region due to large patient population, less stringent regulatory scenario, increasing R&D investment, growth in clinical trials conducted and government funding for the disease treatment.

The introduction of new players will change the existing market dynamics as they continue to compete with existing key players

The key players in the diabetic neuropathy market are Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals. Due to the high cost associated with the development of novel drugs and long regulatory approval time, the major players in the diabetic neuropathy industry acquire small players possessing unique drugs. The market is consolidated in nature with major pharmaceutical players accounting for major market share. As majority of current breed of drugs undergo patent expiration, the generic drugs will enter the market and the key competitors would have to introduce innovative products into the market to stay competitive.

Click To Reading More On Diabetic Neuropathy Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Diabetic Neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy.

Europe cathepsin inhibitors market is also expected to show a significant growth during the forecast period, owing to frequent research and development activities by key players for the development of new cathepsin inhibitors in the region. For instance, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, is developing RO5459072, a cathepsin S inhibitor, on the immune response to a gluten challenge in volunteers with celiac disease.

Cathepsins are a group of lysosomal proteases (enzymes that degrades protein), found in all animals and other organisms, and perform a key role in cellular protein turnover. Cathepsin family includes serine proteases, aspartic proteases, and cysteine proteases. The aspartyl protease class is composed of cathepsins D and E. The cysteine protease class comprises cathepsins B, L, H, K, S, and O. Cathepsin G includes serine protease class. Currently, there are no approved cathepsin inhibitors in the market, however various research and development activities are under process for the development of novel cathepsin inhibitors for treatment of various conditions such as cancer, traumatic brain injury, Ebola infection, and others.

Erythrocyte sedimentation rate (ESR) analyzer measures the rate, at which the red blood cells or erythrocytes settle in a period of one hour. ESR is usually measured in millimeter per hour (mm/hour). An extremely high ESR value, which is one above 100 mm/hour may indicate the diseases such as multiple myeloma, hypersensitivity vasculitis, and temporal arteritis. ESR analyzer is a common hematological tester, which detects the non-specific inflammation, caused by active infection, cancer, heart disease, kidney disease, blood disease, diabetes, and collagen vascular disease. These analyzers are used in hospitals to measure the sedimentation rate of erythrocytes and red blood cells for reliable and accurate reading. The fully automated ESR analyzers are enable to give the fully automatic analysis of ESR. Semi-Automated ESR analyzers are not fully automatic rather certain operations of those instruments require manual intervention. The advantage of these instruments include smaller size, due to which they can be used in constrained spaces.   

Global ESR Analyzer Market - Drivers

Increasing number of infections leading to various health hazards will contribute to increasing number of ESR tests, which in turn will drive the global ESR analyzer market. According to the World Health Organization, in 2018, healthcare associated infection was about 10% and surgical site infections were 50%.  ESR is one of the basic hematological test, which is performed to identify various disease conditions that would contribute to growth of global ESR analyzer market. Technological upgrades leading to development of automated ESR analyzers would also contribute to the global ESR analyzer market growth.

Request A Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/2813

Furthermore, adoption of advanced semi-automatic and automatic ESR analyzers in the healthcare industry are among the prime factors driving the global ESR analyzer market growth. On the other hand, requirement of lesser workforce and is ultimately fueling the global ESR analyzer market growth. Increase in usage of ESR analyzers in hospitals, diagnostic laboratories, and academic institutions drives growth of the global ESR analyzer market.

Moreover, manufacturers are developing advanced systems such as automated ESR analyzers to provide instant detection rate. For instance, in July 2018, Streck and Diesse Diagnostica Senese introduced the Cube 30 Touch, an automated instrument for high volume erythrocyte sedimentation rate testing in Ethylene diamine tetraacetic acid (EDTA) tubes. The analyzer produces ESR results directly from EDTA tubes without consuming the patient sample. Furthermore, in September 2013, Beckman Coulter, Inc., and IRIS Diagnostics announced the launch of the Alifax automated erythrocyte sedimentation rate (ESR) analysis system through a distribution agreement with Alifax S.r.l.

Key players in the global ESR analyzer market are adopting distribution agreements that allow the company to enhance revenue in various regions. For instance, in March 2017, Sysmex America signed a distribution agreement with Alifax S.r.l. for its erythrocytes sedimentation rate products. Alifax ESR analyzers are an exciting addition in the Sysmex portfolio. In response to the market needs for quick results, the Alifax Test1 and Roller 20, a family of automated analyzers, offer ESR results in 20 seconds.

Global ESR Analyzer Market - Regional Insights

North America holds dominant position in the global ESR analyzer market, owing to increasing incidence of blood related diseases and presence of majority of the manufacturers in this region.

Asia Pacific is expected to gain the highest growth rate during the forecast period, owing to increasing blood borne infections, and inadequate sanitation conditions, which lead to increase infections among population. Moreover, government focuses on the improvement in healthcare infrastructure and providing the better healthcare facilities to the population, which would propel growth of global ESR analyzer market in Asia Pacific.

Global ESR Analyzer Market - Competitive Landscape

Some of the key players operating in the global ESR analyzer market include ALCOR Scientific Inc., Thermo Fisher Scientific, Caretium Medical Instruments Co., LTD, Hospitex Diagnostics, Beckman Coulter Inc., Alifax, Perlong Medical, Streck, Diesse Diagnostica Senese S.p.A, and ELITech Group. 

Click To Reading More On ESR Analyzer Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Erythrocyte sedimentation rate (ESR) analyzer measures the rate, at which the red blood cells or erythrocytes settle in a period of one hour. ESR is usually measured in millimeter per hour (mm/hour).

The global craniomaxillofacial implant market was valued at US$ 1,907.9 million in 2016 and is expected to witness a robust CAGR of 6.2% over the forecast period (2017-2025).

Craniomaxillofacial is a special branch of orthopedic surgery, which focuses on all the aspects of facial and skull disorders. The craniomaxillofacial implant surgery is carried out to treat a severe injury of facial and cranial bones, where the implants are temporarily or permanently placed in the body. Traumas, accidents, and genetic defects lead to craniomaxillofacial deformities.

Craniomaxillofacial is a special branch of orthopedic surgery, which focuses on all the aspects of facial and skull disorders. The craniomaxillofacial implant surgery is carried out to treat a severe injury of facial and cranial bones, where the implants are temporarily or permanently placed in the body. Traumas, accidents, and genetic defects lead to craniomaxillofacial deformities. Craniomaxillofacial implants surgery is also carried out to correct abnormalities and deformities caused by diseases, such as Crouzon’s disease and Apert’s Syndrome. Initially, the emphasis was just on keeping absolute stability of the bones, without much attention on free movements. However, owing to advancements in technology and implant materials such as biocompatible titanium implants, resorbable plates, screws, and bone grafts, have increased the scope for maintaining stability as well as functionality of the joints, allowing for ease of treatments related to craniomaxillofacial deformities. Furthermore, lack of other alternatives for facial surgeries is expected to favor the craniomaxillofacial implants market. Birth defects such as cleft palate and anotia are also treated through craniomaxillofacial surgeries. According to the Centers for Disease Control and Prevention in the U.S., around 2,650 babies are recorded to be born with a cleft palate, every year. Improvement in implant materials and minimal invasiveness of this type of surgery is increasing its demand among the populace.

Few growth restraining factors are the high costs associated with craniomaxillofacial surgeries and low availability of skilled surgeons.

The global craniomaxillofacial implant market was valued at US$ 1,907.9 million in 2016 and is expected to witness a robust CAGR of 6.2% over the forecast period (2017-2025).

Request A Sample Copy:

http://bit.ly/32rZjFj

North America was the dominant region in 2016 and accounted the largest share in the global craniomaxillofacial implants market followed by Europe. The major factor for the dominance of North America in craniomaxillofacial implants market is the high presence of skilled surgeons in the region. According to Center for Disease Control and Prevention in the U.S., around 2 million high school athletes are reported with injuries annually, in which head injuries accounted for 14% each year. Asia Pacific is expected to witness the largest growth rate in the craniomaxillofacial implants market during the forecast period. Factors such as rising expenditure on healthcare by the population and increasing rate of sports-related injuries will augment growth of craniomaxillofacial implants market. Furthermore, old people are prone to higher risk injuries due to their weak skeletal system, and an increasing geriatric pupation will boost the growth of craniomaxillofacial implants market in the near future. According to National Institute on Aging, 524 million people were recorded to be 65 years of age and above in the U.S., accounting for 8% of the world's population in 2010. Also estimates from the same source, by 2050 the population of U.S. will be around 1.5 billion, three times more than in 2010, representing 16% of the world's population.

Improved craniomaxillofacial implant materials and advent of new technologies associated with surgeries are expected to drive the craniomaxillofacial implants market

Patient specific implants, 3D implants, growing demand for bioresorbable materials, and growing adoption of robot assisted surgeries have simplified the complexity of craniomaxillofacial surgeries. Whereas, advanced techniques, including computer-assisted craniofacial reconstruction, distraction osteogenesis, and endoscopic procedures, combined with refinements in surgical equipment such as resorbable plating and distractors, have improved surgical outcomes, while minimizing morbidity. The development of bone graft substitutes with the help of gene therapy and nanotechnology is also expected to drive the craniomaxillofacial implants market.

Some major players operating in the craniomaxillofacial implants market include Stryker Corporation, Johnson & Johnson, Zimmer Biomet Holdings, Inc., Medtronic plc, Integra LifeSciences Holdings Corporation, OsteoMed L.P., Medartis AG, KLS Martin, Calavera Surgical Design, and Matrix Surgicssal USA.

Click To Reading More On Craniomaxillofacial Implants Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. The disease leads in malfunction of the nervous system to communicate, which in turn causes several signs and symptoms, including physical, mental, and psychiatric problems. Double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination are some of the other symptoms. The types of MS include relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). RPMS is the most common type characterized by defined attacks with increasing neurological symptoms, PPMS is the rare form characterized by gradual progression of disease, whereas SPMS is commonly identified in people living with relapsed-remitting MS. The most common symptoms of the disease include partial or complete vision loss, prolonged vision loss, lack of coordination, and slurred speech.

A combination of genetic and environmental factors is responsible for the occurrence of the condition. According to a study by International Progressive Alliance, 2013, MS is two to three times more common in women than in men, suggesting that hormones play a significant role in determining susceptibility to the disease.

The global multiple sclerosis therapeutics market was valued at US$ 19.6 billion in 2016 and is expected to witness a robust CAGR of 2.5% over the forecast period (2017 – 2025).

Request A Sample Copy:

http://bit.ly/32sEGbS

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000 population. North America dominates the multiple sclerosis therapeutics market owing to the high prevalence of the condition and the rising economic burden of the disease leading to the adoption of novel therapeutics. According to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Higher therapy cost is restraining the growth of the multiple sclerosis therapeutics market.

Intensive R&D programs undertaken by organizations to accelerate the market growth     

Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, contributing to be a vital factor driving the growth of global multiple sclerosis therapeutics market. For instance, the scientists at Multiple Sclerosis International Federation are undertaking research to understand, manage and treat the disease and are currently undertaking clinical trials to investigate the potential of stem cell therapies including mesenchymal stem cell (MSCs), hematopoietic stem cells (HSCs) and neural stem cells (NSCs). Also, in 2013, the Progressive MS Alliance was established to specifically research and develop more treatment options for people with the progressive forms of MS which currently has a total of 20 projects with researchers based in nine countries. Additionally, in 2015, the MS Society of Canada and the Canadian Institute of Health Research funded a new research to the University of Alberta to examine novel therapeutic strategy to reduce inflammation in the brain, a key factor contributing to the muscle disability associated with multiple sclerosis.

The major players operating in the global multiple sclerosis therapeutics market include Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.

Click To Reading More On Multiple Sclerosis Therapeutics Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com